Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Hershberg, Uri ^a,b   Meng, Wenzhao ^c   Zhang, Bochao ^a   Haff, Nancy ^c   St Clair, E W ^d   Cohen, Philip L ^e   McNair, Patrice D ^d   Li, Ling ^f   Levesque, Marc C ^f   Luning Prak, Eline T ^c  

^a DREXEL UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN HEAVY CHAIN DH; IMMUNOGLOBULIN HEAVY CHAIN JH; IMMUNOGLOBULIN HEAVY CHAIN VH; METHYLPREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL CLONE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE SILENCING; HEAVY CHAIN; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN GENE; MEMORY CELL; SEQUENCE ANALYSIS; SJOEGREN SYNDROME; SOMATIC MUTATION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOLOGY; PATHOLOGY; SJOGREN'S SYNDROME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CLONE CELLS; FLOW CYTOMETRY; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; SJOGREN'S SYNDROME;

EID: 84895765184     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4481     Document Type: Article

References (58)

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58:15-25. National Arthritis Data Workgroup.
2. Singh N, Cohen PL. The T cell in Sjogren's syndrome: force majeure, not spectateur. J Autoimmun 2012, 39:229-233. 10.1016/j.jaut.2012.05.019, 3428488, 22709856.
3. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, et al. American college of rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International collaborative clinical alliance cohort. Arthritis Care Res 2012, 64:475-487.
4. Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjogren's syndrome. Arthritis Rheum 2010, 62:2605-2610. 10.1002/art.27564, 20496425.
5. Smith AJ, Gordon TP, Macardle PJ. Increased expression of the B-cell-regulatory molecule CD72 in primary Sjogren's syndrome. Tissue Antigens 2004, 63:255-259. 10.1111/j.1399-0039.2004.00187.x, 14989715.
6. Saadoun D, Terrier B, Bannock J, Vazquez T, Massad C, Kang I, Joly F, Rosenzwajg M, Sene D, Benech P, Musset L, Klatzmann D, Meffre E, Cacoub P. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren's syndrome-associated lymphoproliferation. Arthritis Rheum 2013, 65:1085-1096.
7. Pers JO, D'Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. Is periodontal disease mediated by salivary BAFF in Sjogren's syndrome?. Arthritis Rheum 2005, 52:2411-2414. 10.1002/art.21205, 16052575.
8. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007, 25:587-617. 10.1146/annurev.immunol.25.022106.141553, 17378764.
9. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113:5418-5422. 10.1182/blood-2008-12-195008, 2689043, 19234139.
10. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, Marti GE, Caporaso NE. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009, 360:659-667. 10.1056/NEJMoa0806122, 19213679.
11. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Med 2012, 91:1-9.
12. Hansen A, Reiter K, Pruss A, Loddenkemper C, Kaufmann O, Jacobi AM, Scholze J, Lipsky PE, Dorner T. Dissemination of a Sjogren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum 2006, 54:127-137. 10.1002/art.21558, 16385504.
13. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750. 10.1002/art.21260, 16142737.
14. Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the autoImmune and rituximab registry. Ann Rheum Dis 2013, 72:1026-1031. 10.1136/annrheumdis-2012-202293, 23264337.
15. St Clair EW, Levesque MC, Luning Prak ET, Vivino FB, Alappatt CJ, Spychala ME, Wedgwood J, McNamara J, Moser Sivils KL, Fisher L, Cohen P. Rituximab therapy for primary sjogren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013, 65:1097-1106. 10.1002/art.37850, 23334994.
16. Rouziere AS, Kneitz C, Palanichamy A, Dorner T, Tony HP. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 2005, 7:R714-R724. 10.1186/ar1731, 1175025, 15987473.
17. Palanichamy A, Roll P, Theiss R, Dorner T, Tony HP. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Arthritis Rheum 2008, 58:3665-3674. 10.1002/art.24141, 19035487.
18. Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, Amos JD, Gurley TC, Allgood S, Haynes BB, Vandergrift NA, Plonk S, Parker DC, Cohen MS, Tomaras GD, Goepfert PA, Shaw GM, Schmitz JE, Eron JJ, Shaheen NJ, Hicks CB, Liao HX, Markowitz M, Kelsoe G, Margolis DM, Haynes BF. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009, 6:e1000107. 10.1371/journal.pmed.1000107, 2702159, 19582166.
19. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, Parks R, Whitesides J, Marshall DJ, Hwang KK, Yang Y, Chen X, Gao F, Munshaw S, Kepler TB, Denny T, Moody MA, Haynes BF. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 2009, 158:171-179. 10.1016/j.jviromet.2009.02.014, 2805188, 19428587.
20. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, Wu Y, Gemrot E, Brochet X, Lane J, Regnier L, Ehrenmann F, Lefranc G, Duroux P. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009, 37:D1006-D1012. 10.1093/nar/gkn838, 2686541, 18978023.
21. Alamyar E, Giudicelli V, Li S, Duroux P, Lefranc MP. IMGT/HighV-QUEST: the IMGT(R) web portal for immunoglobulin (IG) or antibody and T cell receptor (TR) analysis from NGS high throughput and deep sequencing. Immunome Res 2012, 8:26.
22. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948. 10.1093/bioinformatics/btm404, 17846036.
23. Uduman M, Yaari G, Hershberg U, Stern JA, Shlomchik MJ, Kleinstein SH. Detecting selection in immunoglobulin sequences. Nucleic Acids Res 2011, 39:W499-W504. 10.1093/nar/gkr413, 3125793, 21665923.
24. MacDonald CM, Boursier L, D'Cruz DP, Dunn-Walters DK, Spencer J. Mathematical analysis of antigen selection in somatically mutated immunoglobulin genes associated with autoimmunity. Lupus 2010, 19:1161-1170. 10.1177/0961203310367657, 20501523.
25. Shapiro GS, Aviszus K, Murphy J, Wysocki LJ. Evolution of Ig DNA sequence to target specific base positions within codons for somatic hypermutation. J Immunol 2002, 168:2302-2306.
26. Cowell LG, Kepler TB. The nucleotide-replacement spectrum under somatic hypermutation exhibits microsequence dependence that is strand-symmetric and distinct from that under germline mutation. J Immunol 2000, 164:1971-1976.
27. Hershberg U, Shlomchik MJ. Differences in potential for amino acid change after mutation reveals distinct strategies for kappa and lambda light-chain variation. Proc Natl Acad Sci U S A 2006, 103:15963-15968. 10.1073/pnas.0607581103, 1635110, 17038496.
28. Smith DS, Creadon G, Jena PK, Portanova JP, Kotzin BL, Wysocki LJ. Di- and trinucleotide target preferences of somatic mutagenesis in normal and autoreactive B cells. J Immunol 1996, 156:2642-2652.
29. Hershberg U, Uduman M, Shlomchik MJ, Kleinstein SH. Improved methods for detecting selection by mutation analysis of Ig V region sequences. Int Immunol 2008, 20:683-694. 10.1093/intimm/dxn026, 18397909.
30. Yaari G, Uduman M, Kleinstein SH. Quantifying selection in high-throughput Immunoglobulin sequencing data sets. Nucleic Acids Res 2012, 40:e134. 10.1093/nar/gks457, 3458526, 22641856.
31. The BASELINe program can be obtained from the Kleinstein Laboratory. [http://medicine.yale.edu/labs/kleinstein/www/software.html].
32. Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, De Vita S. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013, 52:276-281. 10.1093/rheumatology/kes180, 22879463.
33. Guzman LM, Castillo D, Aguilera SO. Polymerase chain reaction (PCR) detection of B cell clonality in Sjogren's syndrome patients: a diagnostic tool of clonal expansion. Clin Exp Immunol 2010, 161:57-64. 2940149, 20408860.
34. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's Syndrome Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002, 61:554-558. 10.1136/ard.61.6.554, 1754137, 12006334, European Study Group on Classification Criteria for Sjögren's Syndrome.
35. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, Ni I, Mei L, Sundar PD, Day GM, Cox D, Rajpal A, Pons J. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 2009, 106:20216-20221. 10.1073/pnas.0909775106, 2787155, 19875695.
36. Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjogren's syndrome after B cell depletion therapy. Ann Rheum Dis 2012, 71:1881-1887. 10.1136/annrheumdis-2011-201189, 22615459.
37. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007, 179:3351-3361.
38. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther 2013, 15:S3.
39. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010, 10:301-316. 10.1038/nri2761, 20414204.
40. Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 2006, 176:6405-6410.
41. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003, 62:168-171. 10.1136/ard.62.2.168, 1754442, 12525388.
42. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007, 66:700-703. 10.1136/ard.2006.060772, 1954605, 17040963.
43. Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG, Meijer JM, Visser A, Huitema MG, Spijkervet FK, Kallenberg CG, Bootsma H, Kroese FG. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 2013, 72:146-148. 10.1136/annrheumdis-2012-202071, 22851468.
44. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671. 10.1038/nature06890, 2515609, 18449194.
45. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. Structural repertoire of the human VH segments. J Mol Biol 1992, 227:799-817. 10.1016/0022-2836(92)90224-8, 1404389.
46. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273. 10.1038/nsmb.1566, 2692245, 19234466.
47. Stewart A, Harrison JS, Regula LK, Lai JR. Side chain requirements for affinity and specificity in D5, an HIV-1 antibody derived from the VH1-69 germline segment. BMC Biochem 2013, 14:9. 10.1186/1471-2091-14-9, 3626704, 23566198.
48. Perotti M, Ghidoli N, Altara R, Diotti RA, Clementi N, De Marco D, Sassi M, Clementi M, Burioni R, Mancini N. Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun Rev 2008, 7:468-472. 10.1016/j.autrev.2008.03.008, 18558364.
49. De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G, Boiocchi M. Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 2002, 32:903-910. 10.1002/1521-4141(200203)32:3<903::AID-IMMU903>3.0.CO;2-D, 11870635.
50. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000, 95:3878-3884.
51. Carbonari M, Caprini E, Tedesco T, Mazzetta F, Tocco V, Casato M, Russo G, Fiorilli M. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005, 174:6532-6539.
52. Lindop R, Arentz G, Chataway TK, Thurgood LA, Jackson MW, Reed JH, McCluskey J, Gordon TP. Molecular signature of a public clonotypic autoantibody in primary Sjogren's syndrome: a " forbidden" clone in systemic autoimmunity. Arthritis Rheum 2011, 63:3477-3486. 10.1002/art.30566, 22038404.
53. Briney BS, Willis JR, Hicar MD, Thomas JW, Crowe JE. Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire. Immunology 2012, 137:56-64. 10.1111/j.1365-2567.2012.03605.x, 3449247, 22612413.
54. Klonowski KD, Primiano LL, Monestier M. Atypical VH-D-JH rearrangements in newborn autoimmune MRL mice. J Immunol 1999, 162:1566-1572.
55. Silverman GJ, Goldfien RD, Chen P, Mageed RA, Jefferis R, Goni F, Frangione B, Fong S, Carson DA. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. J Clin Invest 1988, 82:469-475. 10.1172/JCI113620, 303536, 3136191.
56. Shlomchik M, Nemazee D, van Snick J, Weigert M. Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). II. Comparison of hybridomas derived by lipopolysaccharide stimulation and secondary protein immunization. J Exp Med 1987, 165:970-987. 10.1084/jem.165.4.970, 2188567, 3494096.
57. Carl PL, Temple BR, Cohen PL. Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity. Arthritis Res Ther 2005, 7:R1360-R1374. 10.1186/ar1832, 1297582, 16277689.
58. Kang CY, Cheng HL, Rudikoff S, Kohler H. Idiotypic self binding of a dominant germline idiotype (T15). Autobody activity is affected by antibody valency. J Exp Med 1987, 165:1332-1343. 10.1084/jem.165.5.1332, 2188311, 3106554.